ESC 365 - State of the Art: P2Y12 inhibitors in acute coronary syndromes

ESC Premium Access

State of the Art: P2Y12 inhibitors in acute coronary syndromes

Session: P2Y12 inhibitors in acute coronary syndromes

Topic: Thrombosis and platelets

Speaker: Professor D. Bhatt (New York, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York (United States of America)

44 presentations

7 followers

4 more presentations in this session

Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction in relation to renal function: 1-year SWEDEHEART registry data.

Speaker: Doctor R. Edfors (Stockholm, SE)

Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry.

Speaker: Doctor P. Riedmaier (Ludwigshafen, DE)

The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction : a systematic review and meta-analysis

Speaker: Doctor A. Bellemain-Appaix (Antibes, FR)

Future perspectives for antithrombotic strategy after acute coronary syndromes

Speaker: Professor R. Storey (Sheffield, GB)

Access the full session

P2Y12 inhibitors in acute coronary syndromes

Speakers: Professor D. Bhatt, Doctor R. Edfors, Doctor P. Riedmaier, Doctor A. Bellemain-Appaix, Professor R. Storey

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources